Macleods Pharma USA Recalls Thousands of Blood Pressure Medication Bottles Nationwide
Just the facts

Macleods Pharma USA Recalls Thousands of Blood Pressure Medication Bottles Nationwide

Summary

Macleods Pharma USA is recalling over 3,700 bottles of Olmesartan Medoxomil, Amlodipine and Hydrochlorothiazide tablets after the FDA found they failed dissolution testing.

Macleods Pharma USA, based in New Jersey, announced a nationwide recall of certain lots of a combination blood-pressure medication containing Olmesartan Medoxomil, Amlodipine and Hydrochlorothiazide. The U.S. Food and Drug Administration said the products did not meet dissolution specifications, a quality standard that ensures tablets dissolve properly during use.

The recall includes 3,528 bottles of 30 tablets (lot 12251163A) and 216 bottles of 90 tablets (lot 12251163B), both bearing an expiration date of May 31, 2027. Consumers can identify the affected products by the lot numbers and National Drug Code (NDC) 33342-246-07 for the 30-count bottles and 33342-246-10 for the 90-count bottles.

The FDA classified the action as a Class II recall, indicating that use of the medication may cause temporary or medically reversible health effects, though serious consequences are considered unlikely. The recall, initiated on Oct. 7 and classified on Oct. 26, remains ongoing and covers products distributed across the United States.

"The recall is due to failed dissolution specifications, meaning the pills did not dissolve as required during testing," the FDA stated.

Macleods Pharma USA could not be reached for comment at the time of reporting.

Keep reading — for free

Create a free account to follow the news. No card required.